Product
OH2
Aliases
OH2 injection
Name
OH2
10 clinical trials
1 drug
8 indications
Indication
MelanomaIndication
Central Nervous System TumorsIndication
Liver CancerIndication
Non-muscle-invasive Bladder CancerIndication
Solid TumorIndication
Bladder CancerIndication
Gastrointestinal CancerIndication
Pancreatic CancerDrug
OH2Clinical trial
To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard TherapyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Clinical Study of Oncolytic Virus (OH2) Injection in the Treatment of Patients Undergoing Surgery After Recurrence of Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2024-06-16
Clinical trial
Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of MelanomaStatus: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety ,Tolerance and Pharmacokinetics of OH2 Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver CancerStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Open and Incremental Phase I Clinical Trial of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) in the Treatment of Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-13
Clinical trial
Oncolytic Virus (OH2) Adjuvant Therapy After Transurethral Resection of Bladder Tumor in Non-Muscle-Invasive Bladder Cancer Who Have Failed First-line Prophylactic Intravesical Instillation Therapy: a Phase Ⅰb/Ⅱ Clinical TrialStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Phase Ib/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Pancreatic CancerStatus: Terminated, Estimated PCD: 2023-05-04
Clinical trial
A Phase 1, Open-label Study of OH2, an Oncolytic Virus, Administered by Intratumoral Injection in Patients With Advanced/Metastatic Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Efficacy and Safety Study of Oncolytic Virus (OH2) Intratumoral Injection in Locally Advanced or Metastatic Bladder Cancer a Phase Ⅱ Clinical TrialStatus: Recruiting, Estimated PCD: 2024-07-01